Latest Period
n/a
Security Snapshot
Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) Institutional Ownership
CUSIP: 28623U101
13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.38
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- ELEV
- Shares outstanding
- 62,337,402
- SEC-reported price per share
- $0.38
- Insider filing price
- $0.38
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ELEV - Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 28623U101.
- Latest finished 13F holder period is not available.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
- SEC-reported value moved from $720 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
28623U101
Latest holder period
n/a
13F holders
13D/G owners
5
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28623U101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
ELEV
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 7% | $1,642,800 | 4,440,000 | BVF PARTNERS L P/IL | 31 Mar 2025 | |||
| TANG CAPITAL MANAGEMENT LLC | 5% | -50% | $1,183,700 | -$1,112,990 | 3,115,000 | -48% | TANG CAPITAL MANAGEMENT, LLC | 30 Jun 2025 |
| VANGUARD GROUP INC | 4.4% | $965,717 | 2,610,045 | The Vanguard Group | 31 Dec 2024 | |||
| GOLDMAN SACHS GROUP INC | 2.8% | $622,842 | 1,683,356 | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2024 | |||
| BlackRock, Inc. | 0.6% | -96% | $135,478 | -$1,025,726 | 369,048 | -88% | BlackRock, Inc. | 30 Jun 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
n/a
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$720 | $0.38 | 0 |
| 2025 Q3 | 2,000 | $720 | -$10,839,974 | $0.36 | 1 |
| 2025 Q2 | 29,539,370 | $10,842,560 | -$793,553 | $0.37 | 62 |
| 2025 Q1 | 33,845,637 | $8,763,416 | -$4,443,040 | $0.26 | 70 |
| 2024 Q4 | 39,972,031 | $22,485,572 | -$3,751,363 | $0.56 | 70 |
| 2024 Q3 | 45,935,957 | $27,556,513 | -$42,322,821 | $0.60 | 67 |
| 2024 Q2 | 52,117,516 | $140,353,793 | +$17,122,980 | $2.70 | 79 |
| 2024 Q1 | 43,980,695 | $225,620,623 | +$110,373,555 | $5.13 | 61 |
| 2023 Q4 | 25,848,863 | $13,880,951 | -$1,444,451 | $0.54 | 31 |
| 2023 Q3 | 28,047,314 | $18,583,583 | -$5,577,531 | $0.66 | 40 |
| 2023 Q2 | 31,537,990 | $48,818,036 | +$22,972,167 | $1.52 | 38 |
| 2023 Q1 | 16,241,361 | $30,858,572 | +$3,765,785 | $1.90 | 27 |
| 2022 Q4 | 14,423,778 | $13,696,323 | +$91,721 | $0.95 | 26 |
| 2022 Q3 | 14,278,557 | $16,134,000 | -$1,527,236 | $1.13 | 21 |
| 2022 Q2 | 15,368,572 | $21,517,000 | -$7,037,226 | $1.40 | 24 |
| 2022 Q1 | 18,712,566 | $47,158,000 | +$631,515 | $2.52 | 28 |
| 2021 Q4 | 15,932,443 | $95,906,000 | -$3,116,582 | $6.02 | 33 |
| 2021 Q3 | 15,882,998 | $123,294,000 | -$8,545,986 | $7.79 | 21 |
| 2021 Q2 | 16,192,115 | $217,244,000 | +$217,244,000 | $13.57 | 35 |